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Abstract
Normal testosterone level is influencing all the steps of the male psychosexual devel-
opment: intrauterine neonatal and final psychosexual development.. At pubertal stage, 
the quality of testosterone secretion is conditioning the development of the mature male 
phenotype. In adult life, eugonadism sustains desire, arousal, determines spontaneous 
erections, facilitates stimulated erection, influencing the response rate to medication. 
Moreover, eugonadism sustain daydreaming and phantasies, both needed for a normal 
sexual life. The pathogenic mechanism of all these actions is presented. Talking about 
hypogonadism means not only the classical types of hypogonadism: due to classical 
testicular disease of central, hypothalamic and hypophysis disease, but also the partial 
testosterone deficiency induces by aging (late onset hypogonadism), weight increase (up 
to 30% of males with metabolic syndrome and 50% of males with diabetes) or secondary 
hypogonadism described in chronic use of steroids or after long exposure to stress, espe-
cially in young males. All these types of hypogonadism, that affect young, middle aged 
or old males will be presented separately. A therapeutic approach that is individualized 
for each type of hypogonadism, should consider positive and possible negative effects 
and all alternatives will be presented: life style changes, sustained weight loss, increase 
exercise, supplemental therapy, pro fertility treatment.
Keywords: male sexual function, hypogonadism, late-onset hypogonadism, testosterone, 
supplemental treatment
1. Introduction
Testosterone is an essential hormone that influences part of sexual function in males.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Androgens directly influence the formation of male genital structures as an active process, 
start in the intrauterine life, sustain the phenotypic complete adult male pattern during devel-
opment in puberty, and maintain the male phenotype during the entire life. Also androgens, 
together with other sexual steroids, do regulate sexual behavior, testosterone being the prin-
cipal determinant of the sex drive not only in males but also in females. Male sexual response 
involves the presence of erection, a phenomenon influenced/sustained and modulated by 
testosterone levels. In these cases, the response rate to treatment is also dependent on the 
intratesticular testosterone. Psychosexual development is also conditioned by testosterone 
presence during childhood and puberty. Testosterone deficiency, regardless of inherited 
diseases, iatrogenic causes, metabolic disease or acquired causes, will impair normal sexual 
life and will condition the response to hormonal and non-hormonal treatment. Testosterone 
deficiency should be considered not only in the classical hypogonadism cases, with central 
or peripheral forms of disease, but also in the more frequent cause of subclinical, late onset 
of disease that affects half of the diabetic population, 30% of the metabolic syndrome male 
population and some of the elderly male population.
2. Role of testosterone in sexual function in males
Normal sexuality in both male and women presumes a normal phenotypic structure, sexual 
identity development and sexual orientation. Especially in males, testosterone influences 
all aspects of normal sexual function. In order to develop a normal sexual response, we 
need complete, congruent or not, sexual structures, sexual development and psychosexual 
components.
2.1. Testosterone effects in male sexualization: organic aspects
After the fertilization of the egg, the chromosomal sex is formed. According to the karyoptype 
[1], there are two ways of evolution:
The active way: In the presence of the sexual active chromosome Y, mainly the SRY gene, located 
on the short arm, favors the preprogrammed male gonadic development. The expression of SRY 
induces the organization of indifferent gonads to Sertoli cell differentiation [2], Antimullerian 
hormone production (AMH) [3], and secondary to testosterone synthesis from the Leydig cells 
[4]. The androgen presence will generate the evolution of Wolff tract structure (paracrine effect 
on the homonymous site) masculinization of the external genitals (weeks 12–16) and involution 
of Muller tract structures. Notably, testosterone in order to be active at the external genital ridge 
has to be converted to 5 α-dihydrotestosterone. Also, the testicular descent from the abdominal 
cavity is a dihydrotestosterone-dependent phenomenon. Normal testosterone levels, normal 
enzymatic apparatus and also normal testosterone receptor activity are needed to obtain the 
physiological effects.
The passive way: Feminization appears only in the absence of active Y chromosome expressing 
SRY gene, when regardless of the karyotype (46XX, 46 XY, 45X, 45 XX/45 XY), their  evolution 
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follows the free, automatic female gonad development, that only starts after the 3rd month of 
intra-gestational development [5]. In the absence of testosterone, there is an involution of the 
Wolff tract structures with a spontaneous, preprogramed differentiation of Muller tract struc-
tures: fallopian tubes, uterus and superior one-third of the vagina. Figure 1 summarizes the 
intrauterine changes in the genital area in both the sexes.
We can consider that the steroids have a major function in somatosexual development: orga-
nizational function—in the development phases, causing permanent changes in the body but 
also in the brain, and an activational function, active later in life, which will guide behavior.
The dismorphic brain changes are described by numerous studies. Testosterone is considered 
to be anxiolytic, anti-depressant and facilitates spatial abilities [6].
The postnatal somatosexual differentiation comprises small changes during early childhood. 
There are minimal somatic differences between sexes, steroid-independent: more female sex 
babies, boys are lesser maturated compared to girls, growth increase sooner in girls than boys, 
with increased size of extremities, increased mandibula, flattening of the trunk with impor-
tant changes in cognition [7].
The puberty period represents the major second transformation period, both in genital and 
in nongenital spheres [8]. Secondary to the hypothalamus-hypophysis axis disinhibition, 
Figure 1. Scheme of the somatosexual differentiation in the intrauterine period.
Hypogonadism in Male Sexual Dysfunction
http://dx.doi.org/10.5772/intechopen.69107
35
between 8 and 13 years of age in females and 9–13.5 years of age in boys, the production of sex-
ual steroids increases dramatically and significant bodily changes appear secondary to expo-
sure to sexual steroids. The somatic changes are measurable by the Tanner stage evaluation of 
secondary sexual characters (breast and pubic hair development in girls, external genitals and 
pubic hair in boys). In males, the following changes are described, all androgen dependent [9]: 
testosterone-dependent effects are increase in muscular mass, bone growth, growth of larynx 
and deepening of voice, inhibition of breast development, stimulation of spermatogenesis, 
whereas the dihydrotestosterone-dependent effects are phallic growth, development of pubic 
hair, and activity of sebaceous glands.
Table 1 summarizes the somatic changes observed in puberty, with the onset timing.
At the end of puberty, we have clear somatic differences between males and females, all sex-
ual steroid-dependent [8, 9]. Notably, the full male pattern is present at the end of puberty, 
but the complete emotional evolution is not yet present. This is a high-risk period for sexual 
experiences.
During adulthood, eugonadism is important to maintain and sustain the previous organic 
changes. It has only a permissive role for maintaining normal sexual responses.
Regardless of diseases, aging is associated with physiological hormonal changes. There are 
several studies [10–12] suggesting that aging is one of the major factors involved in sexual 
Male gender Mean age (years)
Increase penis length 11–12
Increase testes volume
Acne 12
Prostate growth 12.5
Pubarche (P2) 12–13
Growth spurt 12–13
Sesamoid bone 13
Accelerate increase in penis diameter 13–14
Axillary hair (AH1) 14–15
Pubarche (P4) 14.5
Voice change 14–15
Facial hair 14–15
Pubarche (P5) 15–16
Complete spermatogenesis 16
Epiphyseal plate closure >17
Table 1. Somatic changes in male puberty.
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functional changes in males. There is physiological involution of all endocrine glands, with 
decreases in thyroid, adrenal and gonadal hormone production [12].
Many epidemiological studies describe a physiological decrease in total and free testosterone 
levels [13–15]. Many changes are described with important sexual symptoms, similar to the 
presence of overt hypogonadism, with important diseases linked to this testosterone defi-
ciency: bone demineralization [16], increased cardiovascular risk [17], frailty [18], weight gain 
[19], dyslipidemia [20] and increased general mortality [21–23].
2.2. Testosterone role in male sexuality: psychosexual aspects
The psychosexual development is conditioned from the beginning in neonatal life.
Psychosexual differentiation refers to gender identity, respectively, self-identification as male 
or female, gender role, comprising different behavior in males and females, gender orientation, 
representing the choice of sexual partner, respectively cognitive differences [24]. Classically, 
gender identity was considered imprinted postnatally only by social attitudes, words, fam-
ily dynamics, comparison of own body to pears, cultural differences, degree of exposure to 
nakedness [24], learning theory (gender identity is shaped by personal models and cultural 
influences, according to the interaction with parents), cognitive development theory (observa-
tion and imitation of behaviors appropriate for each gender), and biosocial interaction (society 
norms influencing subsequent behavior patterns in the childhood) [24].
Testosterone influences cell survival, anatomical connections and neurochemical activity, being 
responsible for brain differences in structure and function [25]. It is known that prenatal andro-
gen exposure influences children’s sex-typed play behavior [26]. Genetic diseases with abnor-
mal sexual steroid hormones can be used in the evaluation of sexual steroid impact on sexual 
identity: exposure to androgenic progestins increases male-typical behavior [27], and exposure 
to antiandrogenic products will decrease female-typical behaviors [28, 29]. There is a correla-
tion between testosterone levels in maternal blood and amniotic fluid and sex-type behavior 
in childhood [30, 31]. Also, the new explanation for the “toy theory” is that androgen exposure 
favors interest for space movements, by influencing the development of visual fields [32, 33].
There is clear evidence that testosterone and dihydrotestosterone exposure can influence 
gender identity [33, 34]. Androgens have a facilitating and not a determinant role in gender 
identity development [35].
During childhood, psychosexual development is mainly socially dependent and not steroid-
dependent: starting at approximately 1 year of age, boys and girls are aware of gender dif-
ferences at an age of 2–3 years of their own gender, at 3 years of the behavior that belongs 
to the gender role, and from age 5 they play with the same gender peers. Before the age of 6 
“sexual—genital” behaviors are reported but have no conscious significance, being just a plea-
sure action. After the age of 6 years, these behaviors are stable due to the juvenile pause. The 
development is free of androgen influence, due to the gonadostat inhibition, that stays till the 
spontaneous disinhibition of gonadotropic-gonadal axis. Still indirect effects are seen.
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Puberty is a period with important changes in psychosexual behavior. In early adolescence, 
exposure to increased testosterone levels in boys will induce increased aggression and social 
dominance [36], whereas premature estrogen exposure in girls will favor mood changes [37]. 
During puberty, steroid hormones-related changes in the frontal lobe are different in boys 
and girls, favoring phonological skills in women and special skills in boys [38].
The hormonal and physical changes that occur during puberty also contribute in indirect 
ways to differences between adolescent boys and adolescent girls. In girls, secondary sexual 
changes will induce social reactions from peers, parents, teachers, and friends. Adolescence is 
associated with changing social roles, and there is good reason to believe that gender social-
ization intensifies at that time of life [39, 40].
During adolescence typical sexual behaviors will appear: in early adolescence physical changes 
dominate, with insecurity, sexual curiosity and exploration. Auto stimulation is reactivated, 
typical sexual in this case, different from the unconscious stimulation in the early child-
hood period. Androgens are the most important hormones that induce sexual drive [41]. 
Monogamously focused relationships, growing maturity, and responsibility characterize mid-
dle adolescence, and late adolescence is the period of beginning of mature sexuality and accu-
mulation of sexual skills.
The relationship between testosterone and sexual behavior is more complex in humans than 
in animals, where sexual receptivity of the female and sexual interest in males is steroid-
dependent [42]. In humans, there is a complex interference between genetic, hormonal, cul-
tural, social, moral, and environmental influences.
In adults, testosterone sustains secondary sexual characters that were previously formed dur-
ing puberty and directly influences all levels of sexual behavior:
Sexual fantasies are linked to testosterone levels, with a bimodal relationship, testosterone 
favors phantasies, and phantasies affect the testosterone levels [43]. Low testosterone levels 
in adult males change sexual interest even at the level of sexual fantasies [44, 45]. Even day-
dreaming is modulated by normal testosterone levels [45, 46].
Autostimulation and sexual actions are active behaviors, dependent on testosterone levels. 
The best evaluation of testosterone’s involvement in these behaviors is represented by dif-
ferent hypogonadism males, due to different causes [47, 48]. Autostimulation is considered a 
testosterone-dependent behavior; some hypogonadism questionnaires (ANDROTEST) con-
sider impaired masturbation as a positive criterium for hypogonadism [49].
2.3. Testosterone implication in male sexual responses
The classic male sexual response as described by Masters’ and Johnson’ comprises the fol-
lowing event succession: excitement, plateau, orgasm, and resolution [42] corresponding to 
different levels of arousal.
The most important sign of excitement is the appearance of erection. There are three types of 
erections.
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2.3.1. Erection
Stimulated erection is the most complicated and sensitive type of erection, appearing trig-
gered by voluntary actions (kissing, touching, reading, seeing, and smelling), verbal or non-
verbal message, anyhow after an interaction with a partner, appearing within few seconds 
after correct sexual stimulation, regardless of the type of stimulation. After stimulation, the 
brain releases stimulatory neurotransmitters (dopamine, nitric oxide, oxytocin, serotonin), 
from oxytoninergic, serotonergic, and dopaminergic neurons located in “erection centers” 
in the limbic system (paraventricular and supraoptic nuclei) that will generate proerectile 
impulses via the parasympathetic system [50–53]. Parasympathetic impulses stimulate the 
spinal parasympathetic reflexogenic erection centers located at level S2–S4 [50] that will 
directly induce the vascular changes in the cavernous bodies, dilatation of arterioles, increased 
blow flow, decreased venous outflow due to compression of the subtunical venular plexuses, 
increase in oxygen pressure raising the penis, with subsidiary contraction of the ischiocaver-
nosus muscles.
Testosterone influences erection both at central and at peripheral levels.
At CNS level, testosterone stimulates the synthesis, storage and release of proerectile neu-
rotransmitters: dopamine, nitric oxide, and oxytocin [54–56].
At spinal level, the somatic innervation (motoneurons) of bulbo- and ischiocavernous muscles 
is testosterone-dependent, meaning that testosterone influences both the rigidity of the erec-
tion and the orgasmic capacity [57, 58].
At the corpus cavernous level, testosterone influences parasympathetic nerves that generate 
oxid nitric, facilitating NO secretion [59]. Testosterone also influences the quality of cavernous 
muscle relaxation, influencing the expression of alpha adrenoreceptors [60, 61]. Also, andro-
gen deprivation favors cavernous muscle smooth cells apoptosis [62].
Testosterone and its metabolites at both central and peripheral neural pathways are crucial 
for maintaining and restoring erectile capacity. The mechanism of enhanced erection with 
testosterone depends not only on the peripheral neural pathway but also on the central neural 
pathway.
• Spontaneous erections are automatic, not controlled by a specific emotional content or re-
sponse, being purely androgen-dependent. The mechanism of this erection is incompletely 
understood, but androgens play an important role [63, 64]. The role of this autonomous 
erection is nutritive for maintaining regular blood flow and oxygenation of the penis. Tes-
tosterone deficiency, depression, sleep apnea and altered REM phase sleep will impair this 
type of erection [65]. This type of erection is a very important diagnostic tool in the evalua-
tion of erectile dysfunction and differentiation of organic from psychogenic erections.
• Mechanical erection is the most “independent” type of erection to testosterone level. The 
somatic pathway is active in cases of stimulated central erections, but also independent, 
in local mechanical stimulation. Testosterone is indirectly influencing this type of erection 
only by changing the properties of the cavernous smooth muscle units.
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Desire is not present in the classical male sexual response but still is a very important step 
in male sexuality. Desire is considered to consist of a drive—biological component, cultural 
component (wish) and motivational component (individual and relational psychology) [66]. 
Testosterone and other androgens sustain the drive component [67].
3. Testosterone deficiency
In all cases of hypogonadism, major sexual symptoms are described [68–70]:
• Alteration of sexual desire and arousal with a significant decrease in frequency of sexual 
activity
• Decrease/altered quality of spontaneous erections
• Partial alteration of psychic erections: decrease in frequency, amplitude, and rigidity
• Alteration of orgasm and ejaculation proprieties
• Altered response to phosphodiesterase-5 inhibitors
The implication of testosterone deficiency is clear, but the level of deficiency where symptoms 
appear is still debatable. Effects of testosterone on sexual function are dose-dependent up to a 
level close to the lower limit of normal range. From this threshold level, the effects are maximal. 
In cases with testosterone levels very close to this limit, the benefits of testosterone replacement 
are minimal. Below the threshold, the sexual function is impaired [67]. Different thresholds 
are described according to the wanted effect of testosterone [71]. Also the threshold value is 
variable and may increase with aging concerning sexual function, higher testosterone levels 
are needed with aging for the same result [72], with possible individual values, according to 
personal sensitivity [73]. The prevalence of sexual symptoms increases as testosterone levels 
decrease: low libido and vigor for values lower than 15 nmol/L (4.3 ng/mL), disturbed sleep 
at values less than 10 nmol/L, neurovegetative symptoms and erectile dysfunction at values 
less than 8 nmol/L (2.3 ng/mL) [71] and 1.5–2 ng/mL for nocturnal erection [74]. Other studies 
describe other testosterone values: below 8.5 nmol/L for erectile dysfunction, below 11 nmol/L 
for decreased frequency of morning erections and below 13 nmol/L for diminished vigor [75].
Because of all this individual variability and also because of different testosterone thresholds 
for different symptoms, there is still no consensus from the major professional societies about 
the definition of hypogonadism [76–78].
3.1. Hypogonadism types
There are several types of hypogonadism that all lead to alteration of testosterone effects on 
target cells:
• Primary hypogonadism is due to different testicular causes: chromosomal diseases (Kline-
felter syndrome being the most frequent disease [79]) or testicular tumors with testosterone 
deficiency after treatment [80]. Orchitis, acquired anorchia, indiopathic testicular atrophy, 
congenital anorchia, 46 XY sexual development disorders, gonadal dysgenetic syndrome, 
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Noonan Syndrome or LH receptor mutations are other causes of possible primary hypo-
gonadism [76].
• Secondary hypogonadism is due to central, hypothalamic or hypophyseal causes: function-
al or tumoral hyperprolactinemia, Kallmann syndrome, isolated LH deficiency, pituitary 
adenomas, autoimmune hypophysitis, iatrogenic pituitary insufficient (surgery, radiother-
apy), CNS tumors Prader-Willi syndrome, congenital adrenal hyperplasia [76].
Both gonad and hypothalamus insufficiency: late onset hypogonadism due to aging or over-
weight or both is a typical mechanism that is seen in late onset hypogonadism. The hypo-
thalamic pulsatile secretion of gonadotropin-releasing hormone is blunted, due to increased 
hypothalamic sensitivity to negative feedback from the peripheral androgens, with preserva-
tion of the responsiveness of the pituitary gonadotrophs. From a peripheral point of view, 
testicular volume as well as Leydig cell mass and reserve function are diminished. There 
is a reduced testosterone secretion with associated loss of nycthemeral variability [81]. The 
combined defects are responsible for a progressive decrease of testosterone level with 1–2% 
per year [14]. Chronic ill men, obesity and metabolic syndrome also determine testosterone 
deficiency in high percentages with a variable prevalence of 25% [82] up to 50% [83]. Taken all 
into consideration up to 20% of all men over 60 years of age have inappropriate testosterone 
levels [84].
• Androgen receptor insensitivity/resistance is a very rare form of hypogonadism, due to 
total or partial androgen receptor insensitivity or 5-alpha reductase deficiency.
Regardless of type of hypogonadism, the clinical picture is dependent on the moment of onset 
of hypogonadism.
Prenatal testosterone deficiency will alter genital development, inducing all possible altera-
tion of external genital aspects and formation: hypospadias, with different severity degrees, 
cryptorhidia, and ambiguous external genitals to female external genitals. These anatomical 
changes will impair future sexual function. The changes are irreversible and need surgical 
treatment for correction. The general surgical rule is to make the surgical treatment as soon as 
possible and to choose the gender, which is easier to be achieved with reconstructive treatment 
[85] but also in accordance to the intrauterine hormonal exposure. The goal is to complete the 
surgical correction till the age of 2 [86]. It is also important to evaluate, in the presence of 
nonfunctional/dysgenetic gonads, to evaluate the malignancy potential and to make the right 
treatment choices [87]. The major problems in many cases are unrecognized and undiagnosed 
at birth and are difficult to treat after 2 years of age because of organic causes and also due 
to the already established gender identity, gender role and sexual orientation. Testosterone 
replacement treatment is imperative, following the moment of physiological onset.
In cases of prepubertal testosterone deficiency, we will always observe a delayed puberty, 
defined in boys as no secondary sexual characters (increase in testes) before the age of 14 [88]. 
In severe causes of hypogonadism, the clinical picture is typical: small testes, cryptorhidia, 
gynecomastia, high-pitched voice, constant linear growth, eunuchoid habitus, sparse body 
and facial hair, decreased bone and muscle mass. From a sexuality point of view, these boys do 
not show sexual interest, have a decreased tendency of autostimulation, and have decreased 
phantasies and dreams. Untreated hypogonadism will affect all the levels of sexuality, with no 
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normal development of sexuality. In the absence of normal androgen impregnation, there will 
be no erectile performance, altered sexual behavior, altered sense of well-being and globally 
affected sexual function [89]. If untreated, there will be no normal development of an adult 
male phenotype with serious impairment of sexual life.
Adult onset testosterone deficiency will induce different symptoms compared to previously 
mentioned forms of hypogonadism. The patients have normal developed genitals, normal 
developed secondary sexual characters, normal sexual function and behavior till the onset of 
hypogonadism. The clinical picture is dominated by metabolic and sexual symptoms. Sexual 
symptoms include loss of libido, erectile dysfunction, decrease in sexual phantasies, loss of 
body hair and hot flushes. Metabolic complications are loss of bone mass, sarcopenia, weight 
gain, increased body fat and increased vascular risk [90–92].
4. Treatment principles in testosterone deficiency in males
4.1. Life style changes
Life style changes are important only in late-onset hypogonadism, significant weight reduc-
tion, decrease of body fat and regular exercise can increase endogenous testosterone level 
[93, 94]. Life style changes can improve testosterone balance, in absence of active hormonal 
replacement treatment [95, 96] but unfortunately significant weight loss of more than 10% is 
difficult to maintain [96]. This is the motif for which, in majority of cases, supplemental treat-
ment is needed [97]. Even if possible results are interesting, in the testosterone normalization 
in diabetic and overweight patients with metabolic syndrome (what is this?), the compliance 
to sustained weight reduction is low in the long run, so decreased testosterone will reappear 
whenever a new weight increase occurs. Testosterone deficiency prevention is still a goal, with 
management and treatment of modifiable factors, such as weight control, regular sport activi-
ties, and decreased alcohol consumption, but in the majority of cases, it is difficult to sustain.
4.2. Testosterone supplemental therapy
Currently, testosterone supplemental therapy is the golden standard for management of tes-
tosterone deficiency symptoms, regardless of physical, psychological or sexual domains [98].
There is no clear consensus for an accepted lower limit of normal testosterone. Various guide-
lines for the diagnosis of hypogonadism are available: late-onset hypogonadism [78] (total tes-
tosterone < 8 nmol/L) should be treated with testosterone therapy, those with total testosterone 
level of 8–12 nmol/L and hypogonadal symptoms should be given a trial of testosterone replace-
ment therapy, and those with total testosterone level > 12 nmol/L are not hypogonadal and 
should not be treated [99]. Other guidelines recommend treatment for values below 8 nmol/L 
only in cases of physical symptoms [76, 100].
Testosterone measurements should be measured in the morning, between 07 and 11 AM, on 
two different days, and both values should be low in order to confirm the testosterone defi-
ciency. Total testosterone measurements are used in order to make a positive diagnosis.
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Interventional studies have shown a beneficial effect of testosterone replacement therapy on 
insulin resistance [101]. The increase in insulin sensitivity is present in obese men [102, 103], 
patients with heart failure [104], with better glycemic controls in diabetic males under testos-
terone replacement therapy [105, 106].
There are some recommendations of active testosterone screening in special risk categories of 
males [76, 100, 107]:
1. Type-2 diabetes mellitus
2. Metabolic syndrome
3. Moderate to severe chronic lung disease
4. Osteoporosis
5. History of infertility
6. Treatment with steroids, opiates and anticonvulsants
7. Alcohol abuse
8. ED or loss of spontaneous erections
9. Loss of sexual desire
The debate is around the type of symptoms that should be addressed for treatment. If correctly 
screened, with validated questionnaires, less than 5% of men with type-2 diabetes is asymp-
tomatic, free of altered erectile performance, no present ED or altered arousal capacity [108].
The main concern in recommended testosterone replacement therapy is the vascular safety 
[109–111] because of the suggestion of increased stroke risk, despite the reduction in major 
adverse cardiovascular events, as death, nonfatal myocardial infarction and stroke. Some 
studies suggest beneficial effects of testosterone on cardiovascular risk factors [112], low tes-
tosterone being associated with increased cardiac mortality [113, 114].
The benefits for the cardio metabolic risk profile are clear, not only in the direction of insulin 
sensitivity, as seen before, but untreated testosterone deficiency is also associated with a four-
fold risk of developing type-2 diabetes in men [97]. Some studies suggest that testosterone 
replacement therapy induces favorable changes in total and low-density lipoprotein profile, 
lipoprotein, body fat composition and glycated hemoglobin levels [108, 115, 116].
Recent studies showed different results suggesting an increase in vascular events in the 
presence of testosterone supplemental therapy [117–119]. Because of this opposing data, 
the FDA (Food and Drug Administration) still recommends that larger interventional stud-
ies are needed to have a definitive conclusion regarding testosterone treatment on cardiac 
safety [120]. Observational studies did not confirm the increase in cardiovascular events in 
long-term follow-up studies [121]. The EMA (European Medicines Agency) had agreed by 
consensus that there is no consistent evidence of an increased risk for heart problems with 
testosterone replacement in men lacking the hormone [122].
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However, caution should be taken in cases with preexisting cardiovascular disease, especially 
in cases with increased hematocrit levels, due to increased primary thrombotic risk [123, 124].
Similar unresolved issues are seen when evaluating the associated presence of the following:
• Obstructive sleep apnea, classically considered a contraindication for testosterone treat-
ment, because of neutral studies, with no worsening of the disease [125–127]
• Lower urinary tract symptoms, which do not worsen under testosterone treatment, as clas-
sically considered [128–130]
• Congestive heart failure is still a relative contraindications for replacement treatment, 
but controversial, since excellent results are seen in testosterone treatment in cases with 
well controlled congestive heart failure [131]. Maybe untreated/uncontrolled heart failure 
should be considered as a contraindication.
• Prostate safety: Prostate cancer is still a contraindication, but positive results start to emerge 
[76] with respect to lack of increased risk of prostate cancer under supplemental therapy. 
Also symptomatic hypogonadal men with localized prostate cancer, treated surgically, 
without active disease can be cautiously considered for testosterone therapy [132–134]
Taking all these recommendations into consideration, testosterone has clear benefits regard-
ing sexual health [97]. There is a significant effect on sexual desire, intercourse satisfaction 
and overall sexual satisfaction, when evaluated with FSFI questionnaire [135]. There are clear 
benefits on erectile function, with satisfactory sexual intercourses after at least 3 months of 
testosterone supplementation [135, 136]. Also, testosterone treatment, in hypogonadal men, 
improves the therapeutical response to phosphodiesterase-5 inhibitors [137], converting non-
responders to responders [138]. In general, testosterone supplementation has a positive effect 
on orgasmic and ejaculatory function [139]. Sexual interest appears after the first 3 weeks of 
use and reaches plateau in 6 weeks [136].
Except the late-onset hypogonadism, classical indications for testosterone supplementation 
are delayed puberty, Klinefelter syndrome, low bone mass in adult hypogonadism, hypopi-
tuitarism, and testicular dysgenesis. The therapy should be started at the appropriate age of 
puberty onset (in prepubertal forms of diseases) or after the clear diagnosis of hypogonadism 
(in postpubertal forms of diseases) [76]. Active follow-up should be performed in patients 
treated with testosterone supplementation therapy [76, 140]:
• Symptoms response at every visit, minimum after 3 months of treatment, and then annually.
• Formulation of specific adverse effects should be evaluated at each visit.
• Testosterone level should be measured periodically, for a correct supplemental therapy at 
3, 6 and 12 months after onset of the treatment.
• All and each adverse event should be reported immediately.
• Bone mineral density should be measured every 1–2 years
• PSA measurement should be performed every 3 months, in the 1st year of treatment and 
then annually
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• Hematocrit measurement should be monitored at 3, 6 and 12 months and, thereafter, 
annually. Whenever the levels increase above 0.54, testosterone treatment should be 
discontinued.
5. Conclusion
When we think about hypogonadism, we should keep in mind not only the classical types of 
hypogonadism due to classical testicular disease of central, hypothalamic and hypophyseal 
disease, but we should also emphasize the partial testosterone deficiency that is described 
due to age increase (late-onset hypogonadism) or secondary to weight increase (up to 30% of 
males with metabolic syndrome and 50% of males with diabetes) or the secondary hypogo-
nadism described after chronic use of steroids or after long exposure to stress, especially in 
young males. All these types of hypogonadism that affect young, middle-aged or old males 
are presented separately. The therapeutic approach should be individualized for each type of 
hypogonadism and should consider positive and possible negative effects. All alternatives are 
presented: life style changes, sustained weight loss, increased exercise, supplemental therapy 
and pro-fertility treatment.
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